Skip to content

Study on Sufentanil and Remazolam for Anesthesia Induction

Reaction surface model of the interaction between rimazolam and sufentanil

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070286
Enrollment
Unknown
Registered
2023-04-07
Start date
2023-04-15
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obstetrics Disease

Interventions

0.6mg/kg group:Remazolam concentration 0.6 mg/kg
0.1mg/kg group:remazolam concentration 0.1mg/kg
0.2mg/kg group:remazolam concentration 0.2mg/kg
0.4mg/kg group:remazolam concentration 0.4mg/kg

Sponsors

Obstetrics & Gynaecology Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Adult female patients, aged from 20 to 40 years old, ASA I grade, BMI 19~24 kg/m2, elective surgery.

Exclusion criteria

Exclusion criteria: 1. Patients with possible difficult airway: modified Mallampati score III grade or IV grade; 2. Anesthetic allergy or contraindication; 3. Patients who took benzodiazepine or opioid or intermittent benzodiazepine every day in the past 3 months or had a history of severe alcohol or drug abuse; 4. Patients with other systemic diseases; 5. Patients with communication difficulties.

Design outcomes

Primary

MeasureTime frame
Sedation score, MOAA/S;Visual laryngoscope examination respiratory tract rating;

Secondary

MeasureTime frame
Electroencephalogram index, BIS;Blood pressure, HBP;Heart rate, HR;Oxygen saturation, SpO2;

Countries

China

Contacts

Public ContactYang Chen

Obstetrics & Gynaecology Hospital, Fudan University

annie.114@163.com+86 136 7166 7155

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026